UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study

Human vaccines & immunotherapeutics, 2022-12, Vol.18 (1), p.1-10

2022

Volltextzugriff (PDF)

Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously

Human vaccines & immunotherapeutics, 2022-11, Vol.18 (5), p.2073747-2073747

2022

Volltextzugriff (PDF)

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents

Human vaccines & immunotherapeutics, 2021-11, Vol.17 (11), p.4689-4700

2021

Volltextzugriff (PDF)

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

Human vaccines & immunotherapeutics, 2018-12, Vol.14 (12), p.2921-2931

2018

Volltextzugriff (PDF)

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa

Human vaccines & immunotherapeutics, 2017-07, Vol.13 (7), p.1505-1515

2017

Volltextzugriff (PDF)

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

The New England journal of medicine, 2016-09, Vol.375 (11), p.1019-1032

2016

Volltextzugriff (PDF)

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Clinical infectious diseases, 2022-04, Vol.74 (8), p.1459-1467

2022

Volltextzugriff (PDF)

Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials

Vaccine, 2019-04, Vol.37 (18), p.2482-2493

2019

Volltextzugriff (PDF)

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial

JAMA network open, 2021-10, Vol.4 (10), p.e2128652-e2128652

2021

Volltextzugriff (PDF)

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials

Vaccine, 2019-10, Vol.37 (43), p.6262-6267

2019

Volltextzugriff (PDF)

Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients

Vaccine, 2021-01, Vol.39 (1), p.6-10

2021

Volltextzugriff (PDF)

Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12–15 months: A phase III, randomized, non-inferiority trial

Vaccine, 2018-09, Vol.36 (38), p.5781-5788

2018

Volltextzugriff (PDF)

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

Human vaccines & immunotherapeutics, 2019-12, Vol.15 (12), p.2865-2872

2019

Volltextzugriff (PDF)

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study

Human vaccines & immunotherapeutics, 2016-12, Vol.12 (12), p.3072-3078

2016

Volltextzugriff (PDF)

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

Journal of the Pediatric Infectious Diseases Society, 2020-04, Vol.9 (2), p.194-201

2020

Volltextzugriff (PDF)

Reactogenicity of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults: Results of the Phase 3 ZOE-50 Trial

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1)

2015

Volltextzugriff (PDF)

A Randomized, Consistency Study Comparing Immunogenicity and Safety of 2 Vaccines Against Measles, Mumps and Rubella (MMR) Administered to Children 12–15 Months of Age

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

1230Reactogenicity of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults: Results of the Phase 3 ZOE-50 Trial

Open forum infectious diseases, 2015-12, Vol.2 (suppl_1), p.S366-S367

2015

Volltextzugriff (PDF)

Adenovirus‐mediated VEGF‐A gene transfer induces bone formation in vivo

The FASEB journal, 2003-06, Vol.17 (9), p.1147-1149

2003

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(11)
Immunology
(11)
Safety
(9)
Female
(8)
Male
(8)
Vaccines
(8)
Biotechnology & Applied Microbiology
(6)
Immunogenicity
(6)
Clinical Trials
(5)
Middle Aged
(5)
Vaccination
(5)
Age
(4)
Aged
(4)
Double-Blind Method
(4)
Hepatitis B
(4)
Herpes Zoster
(4)
Herpes Zoster - Prevention & Control
(4)
Infectious Diseases
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study

Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials

Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients

Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12–15 months: A phase III, randomized, non-inferiority trial

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

Reactogenicity of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults: Results of the Phase 3 ZOE-50 Trial

A Randomized, Consistency Study Comparing Immunogenicity and Safety of 2 Vaccines Against Measles, Mumps and Rubella (MMR) Administered to Children 12–15 Months of Age

1230Reactogenicity of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults: Results of the Phase 3 ZOE-50 Trial

Adenovirus‐mediated VEGF‐A gene transfer induces bone formation in vivo

Suchergebnisse filtern